Request for Information-Landscape Analysis To Leverage Novel Technologies for Chronic Disease Management for Aging Underserved Populations, 73280-73282 [2020-25328]
Download as PDF
73280
Federal Register / Vol. 85, No. 222 / Tuesday, November 17, 2020 / Notices
Diego, California, Court of Federal
Claims No: 20–1439V
109. Richard Dennis Miszewski, West
Allis, Wisconsin, Court of Federal
Claims No: 20–1440V
110. Raiza Halpert and Moshe Halpert
on behalf of J.H., Monroe, New
York, Court of Federal Claims No:
20–1441V
111. Dominique Roberts, Albuquerque,
New Mexico, Court of Federal
Claims No: 20–1442V
112. Timothy Schwalbe, Milwaukee,
Wisconsin, Court of Federal Claims
No: 20–1445V
113. Jennifer Mire, Republic, Missouri,
Court of Federal Claims No: 20–
1449V
114. Douglas J. Hoos, Grand Island,
Nebraska, Court of Federal Claims
No: 20–1450V
115. Kathleen Runser, College Park,
Maryland, Court of Federal Claims
No: 20–1451V
116. Karen Valentine, Boston,
Massachusetts, Court of Federal
Claims No: 20–1453V
117. Peggy Lund, Minnetonka,
Minnesota, Court of Federal Claims
No: 20–1454V
118. Julia Hunt, Brooklyn, New York,
Court of Federal Claims No: 20–
1455V
119. Heather Hayes and Mark Hayes on
behalf of A.H., Cincinnati, Ohio,
Court of Federal Claims No: 20–
1457V
120. Kathryn Becker, Boston,
Massachusetts, Court of Federal
Claims No: 20–1461V
121. Humberto Rodriguez, Stamford,
Connecticut, Court of Federal
Claims No: 20–1464V
122. Erma Lamb, Boston, Massachusetts,
Court of Federal Claims No: 20–
1465V
123. Jennifer Inscoe, Forest, Virginia,
Court of Federal Claims No: 20–
1466V
124. Paula DeBusk, Fayetteville,
Arkansas, Court of Federal Claims
No: 20–1470V
125. Nicole Fortney, Boston,
Massachusetts, Court of Federal
Claims No: 20–1471V
126. Michael Kochenderfer, Boston,
Massachusetts, Court of Federal
Claims No: 20–1472V
127. Julie Roubik on behalf of Estate of
Thomas Roubik, Deceased, Holmen,
Wisconsin, Court of Federal Claims
No: 20–1473V
128. Debra Gadd, Sandusky, Ohio, Court
of Federal Claims No: 20–1474V
129. Michael Mendoza on behalf of
Christian Mendoza, Chino,
California, Court of Federal Claims
No: 20–1475V
VerDate Sep<11>2014
19:46 Nov 16, 2020
Jkt 253001
130. Dianne Byrd, Albuquerque, New
Mexico, Court of Federal Claims
No: 20–1476V
131. Krista Wall, Encinitas, California,
Court of Federal Claims No: 20–
1477V
132. Grace Shain on behalf of H.S.,
Phoenix, Arizona, Court of Federal
Claims No: 20–1478V
133. Angela Butts, Washington, District
of Columbia, Court of Federal
Claims No: 20–1479V
134. Melissa Manie, Moberly, Missouri,
Court of Federal Claims No: 20–
1482V
135. Carmen C. Salas, San Juan, Puerto
Rico, Court of Federal Claims No:
20–1483V
136. Mitzi Lee, Richmond, Virginia,
Court of Federal Claims No: 20–
1484V
137. Kathryn DeLeon on behalf of N.C.,
Boston, Massachusetts, Court of
Federal Claims No: 20–1485V
138. John Michael Dulaney, Boerne,
Texas, Court of Federal Claims No:
20–1488V
139. Peggy McCarter, Greensboro, North
Carolina, Court of Federal Claims
No: 20–1490V
140. Francine Russo, Athens, Georgia,
Court of Federal Claims No: 20–
1491V
141. Kelli Wilson, Caldwell, Idaho,
Court of Federal Claims No: 20–
1492V
142. Melissa Greenberg and Richard
Greenberg on behalf of M.G.,
Boston, Massachusetts, Court of
Federal Claims No: 20–1493V
143. Nina Cupples, Rutherford,
Tennessee, Court of Federal Claims
No: 20–1494V
144. Rodney Burrill, Seattle,
Washington, Court of Federal
Claims No: 20–1495V
145. Veronica Williams, Dallas, Texas,
Court of Federal Claims No: 20–
1499V
146. Maria Ramos, The Woodlands,
Texas, Court of Federal Claims No:
20–1500V
147. Audrey Chinnock, Overland Park,
Kansas, Court of Federal Claims No:
20–1501V
148. Regina Mileouski, Dresher,
Pennsylvania, Court of Federal
Claims No: 20–1502V
149. Luis Rodriguez, Richmond,
Virginia, Court of Federal Claims
No: 20–1503V
150. Debra S. Colgan, White Plains, New
York, Court of Federal Claims No:
20–1505V
151. Kathleen Finn, Boston,
Massachusetts, Court of Federal
Claims No: 20–1506V
[FR Doc. 2020–25287 Filed 11–16–20; 8:45 am]
BILLING CODE 4165–15–P
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Request for Information—Landscape
Analysis To Leverage Novel
Technologies for Chronic Disease
Management for Aging Underserved
Populations
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Request for information.
AGENCY:
The Office of the Assistant
Secretary for Health (OASH) in the
Department of Health and Human
Services, in partnership with other
federal agencies, seeks to gain a more
comprehensive understanding from
health systems, community based
organizations, academic institutions,
non-federal government agencies,
innovators, entrepreneurs, non-profit
organizations, and other relevant
stakeholders regarding innovative
solutions to chronic disease
management leveraging novel
technologies (e.g., artificial intelligence
(AI), biosensors, apps, remote
monitoring, 5G) to optimize compliance
with evidence-based standards of care
in disease states that cause significant
morbidity and mortality in aging
populations in underserved areas (e.g.,
low income, Medicaid-eligible, rural).
OASH will review information collected
in this request for information (RFI) to
better inform federal government
priorities and programs. We also seek to
identify opportunities to strengthen the
U.S. healthcare system, as a whole,
through public-private partnerships in
data sharing, comprehensive analytics
including AI, and other potential
mechanisms. OASH welcomes public
feedback related to how these questions
should be addressed and/or potential
solutions. The set of questions is
available in the SUPPLEMENTARY
INFORMATION section below.
DATES: To be assured consideration,
comments must be received at the email
address provided below, no later than
midnight Eastern Time (ET) on
December 22, 2020.
ADDRESSES: Individuals are encouraged
to submit responses electronically to
OASHcomments@hhs.gov. Please
indicate ‘‘RFI RESPONSE’’ in the
subject line of your email. Submissions
received after the deadline will not be
reviewed. Responses to this notice are
not offers and cannot be accepted by the
federal government to form a binding
contract or issue a grant. Respond
concisely and in plain language. You
may use any structure or layout that
SUMMARY:
E:\FR\FM\17NON1.SGM
17NON1
Federal Register / Vol. 85, No. 222 / Tuesday, November 17, 2020 / Notices
presents your information well. You
may respond to some or all of our
questions, and you can suggest other
factors or relevant questions. You may
also include links to online material or
interactive presentations. Clearly mark
any proprietary information, and place
it in its own section or file. Your
response will become government
property, and we may publish some of
its non-proprietary content.
FOR FURTHER INFORMATION CONTACT: Dr.
Leith States, Chief Medical Officer,
Office of the Assistant Secretary for
Health, (202) 260–2873.
SUPPLEMENTARY INFORMATION:
Background
The Office of the Assistant Secretary
for Health—in partnership with
Division of Cardiovascular Sciences,
National Heart, Lung, and Blood
Institute, National Institutes of Health;
Administration for Community Living;
Agency for Healthcare Quality and
Research; United States Department of
Agriculture; Federal Communications
Commission; and the White House
Office of Science and Technology Policy
—is interested in resources that enhance
quality of life for aging populations by
enabling access to emerging
technologies and access to healthcare
services. The COVID–19 response has
disrupted access to routine and
emergency healthcare services in many,
if not most, communities. It is estimated
that 41 percent of U.S. adults delayed or
avoided medical care due to concerns
over COVID–19 transmission.1 At the
same time, the pandemic resulted in a
strain on the country’s public health
and healthcare infrastructure. The
populations affected most by this
pandemic are those that experienced
inequities in healthcare at baseline.
These inequities are widely understood
to be driven in part by upstream
predictors identified as the social
determinants of health (SDOH)—
conditions in the environment in which
people are born, live, learn, work, play,
worship, and age that affect a wide
range of health, functioning, and
quality-of-life outcomes and risks.2
Related to these social risk factors, the
biological risk factors most closely
associated with increased risk for
COVID–19 include age (65 years and
older) and chronic diseases (e.g., cancer,
chronic kidney disease, Alzheimer’s
disease and related dementias, chronic
obstructive pulmonary disease, heart
1 Available at: https://www.cdc.gov/mmwr/
volumes/69/wr/mm6936a4.htm#T1_down.
2 Available at: https://www.healthypeople.gov/
2020/topics-objectives/topic/social-determinants-ofhealth.
VerDate Sep<11>2014
19:46 Nov 16, 2020
Jkt 253001
disease and stroke, diabetes, and
obesity). Underscoring the vulnerability
of older adults, the highest rates of
hospitalization and death from COVID–
19 are in the older adult population. In
fact, eight in ten COVID–19-related
deaths reported in the United States
have been among adults 65 and older.3
This situation is exacerbated in rural
communities, for example which,
compared to urban areas, are
characterized by a higher percentage of
older adults, higher rates of all-cause
mortality, and lower density of
healthcare infrastructure.4 5 The
pandemic’s further exacerbation of
inequities in healthcare delivery
introduces the opportunity to identify,
develop, deploy and evaluate innovative
technological approaches to chronic
disease management, as well as the
opportunity to mitigate any introduction
of biases that could increase disparities
in healthcare when applying such
innovative approaches. Technological
advances (e.g., artificial intelligence (AI)
driven solutions) have great potential to
improve health outcomes in the aging
population, particularly for those in
underserved areas (e.g., low income,
Medicaid-eligible, rural) by empowering
patients and facilitating integrated
healthcare delivery.
Leveraging data and applying
technologies to improve health for aging
populations in underserved areas is of
interest. These include, for example,
advancing data availability from health
systems (e.g., claims data, electronic
health records, surveillance data, etc.),
applying AI to inform behavior change
through remote patient monitoring, and
assessing risk to then apply appropriate
preventive/acute care—all to mitigate
excess morbidity and mortality from
chronic diseases. The federal
government has taken some action to
demonstrate this interest. For example,
the Collaborative Aging (in Place)
Research Using Technology (CART)
project, a joint effort between the
Veterans Health Administration and the
National Institutes of Health, was
launched to support future applications
of AI and machine learning to improve
health and healthcare delivery through
systematic evaluation of technologies
that enable older adults to remain
independent. These efforts align with
3 Available at: https://www.cdc.gov/coronavirus/
2019-ncov/need-extra-precautions/olderadults.html.
4 Available at: https://www.shepscenter.unc.edu/
wp-content/uploads/dlm_uploads/2017/05/
Snapshot2017.pdf.
5 Available at: https://www.shepscenter.unc.edu/
wp-content/uploads/dlm_uploads/2017/08/
Regional-Differences-in-Urban-and-Rural-MortalityTrends.pdf.
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
73281
the National Artificial Intelligence
Research and Development Strategic
Plan, an interagency product released in
2019, which lays out eight strategic
priority areas for federal investment in
AI research and development. The
utility of these technologies requires
access to patient monitoring
technologies and the data infrastructure
to support analytics and transmission to
integrated care teams (e.g., primary care,
subspecialty care, nursing, pharmacy,
social work, assisted living providers)
that can effectively leverage signals that
emerge within this system. To better
inform the direction of federal efforts,
OASH and its partners seek information
about complementary technological
activities by identifying common
themes (e.g., barriers, opportunities,
gaps), highlighting innovative solutions
to chronic disease management, and
enhancing the potential for joint publicprivate activities to serve aging
populations in underserved areas
focusing on the imperative to
understand and capitalize on
opportunities to develop,
operationalize, and scale innovations in
healthcare and delivery at the
individual and population levels for
aging Americans.
Scope and Assumptions
• The purpose of this RFI is to gain
a more comprehensive understanding of
how health systems, community based
organizations, academic institutions,
non-federal government agencies,
innovators, entrepreneurs, non-profit
organizations, industry and other
relevant stakeholders are approaching
innovative efforts around chronic
disease management (e.g., heart failure,
hypertension, chronic lower respiratory
disorders, cognitive impairment) for
aging populations in underserved areas
(e.g., rural) by leveraging technologydriven solutions (e.g., AI), including
those designed to optimally utilize
future 5G infrastructure.
• Responses may span the continuum
of care including but not limited to
detection, prevention (e.g., falls risk
reduction), education, lifestyle
modification and behavior change (e.g.,
diet, exercise), treatment and
rehabilitation of disease.
• We are interested in novel
approaches and associated frameworks
for collecting data confirming efficacy
and/or effectiveness of technology
solutions with demonstrated
improvements in one or more of the
following measures: Patient outcomes,
access, safety, quality, cost, and value.
• If responses refer to proposed or
ongoing projects, the following
information should be included:
E:\FR\FM\17NON1.SGM
17NON1
73282
Federal Register / Vol. 85, No. 222 / Tuesday, November 17, 2020 / Notices
Description, rationale, study design,
data sources (to include harmonization/
cleaning of data), funding
organization(s), outcomes of interest,
and how such an approach would avoid
increasing disparities in care.
• Responses may include
implications for scaling an intervention
to broader population levels and other
settings.
• The definition of ‘‘AI-driven
solution’’, for the purposes of this RFI,
should be interpreted broadly. We seek
an understanding of innovative
activities across the spectrum of care in
underserved settings for older adults.
• This RFI also seeks to identify
opportunities to strengthen the U.S.
healthcare system through publicprivate partnerships. The RFI seeks to
identify organizations that would be
interested in discussing the form and
function of such collaborations.
Topics
A. Barriers and Opportunities for
Technology-Driven Solutions
1. What barriers (e.g., privacy
concerns, other clinician and patient
barriers) and opportunities are most
relevant for bringing technology-driven
solutions to aging populations in
underserved areas?
2. What federal policies currently
limit the capacity to deploy and scale
technology-driven solutions for aging
populations?
3. What new federal policies could
facilitate the success of technologydriven solutions for aging populations?
4. What are the ways in which
technology-driven solutions are
manifested (e.g., software platforms,
wearables, robotics, etc.) and how is the
integrity of data collected ensured (e.g.,
fidelity, and accuracy of data)?
5. How will training data sets be
established and implemented to drive
effective technology solutions that
improve chronic disease outcomes for
aging populations in rural areas?
6. How will AI solutions be validated?
What metrics will be used to evaluate
the effectiveness of AI/machine learning
algorithms?
7. How will healthcare team and
patient trust in technology solutions be
addressed? How will legal and ethical
issues be addressed for technology
solutions designed for improving
chronic disease outcomes?
8. How will bias and variance be
addressed in machine learning
algorithms for this application? How
will supervised versus unsupervised
learning be used to develop inferences
and patterns from data sources? What
will be the challenges and proposed
VerDate Sep<11>2014
19:46 Nov 16, 2020
Jkt 253001
solutions for data cleansing and
transformation?
9. Will AI deep learning and neural
networks approaches and solutions be
appropriate and used for chronic
disease improvement for aging
populations?
10. What are the per-person-costs of
technology-driven solutions in the
context of this RFI?
B. Key Indicators & Data Sources of
Technology-Driven Chronic Disease
Management
1. What key indicators or data sets
will be used to perform measure
outcomes (e.g., racial, ethnic, gender,
and socioeconomic disparities)?
2. What existing methods, data
sources, and analytic approaches are
being used to assess and monitor
technology-driven solutions (e.g., AI) in
healthcare systems?
3. What selected health conditions
should be addressed as priority
conditions to assess technology-driven
capacity to influence access, timeliness,
and quality of healthcare treatment and
preventive services to aging populations
living in rural areas?
C. Examples of Health Promotion Using
Technology-Driven Solutions
1. Describe novel technology-driven
approaches (e.g., AI) that may prevent
the onset, progression, or escalation of
chronic disease states in patients who
have decreased frequency of health
system interaction during the COVID–19
pandemic, such as aging Americans
living in rural areas.
2. Outline programs leveraging novel
technology-driven approaches that may
prevent increases in morbidity and
mortality due to deferred care for acute
medical conditions (e.g., exacerbation of
heart failure, decompensated lower
respiratory tract disease).
3. What is the established evidence or
evaluation supporting proposed
benefits, and the evaluation of potential
harms of AI-driven solutions such as
increased racial bias?
D. Public-Private Partnerships
1. Provide ideas of the form and
function of a public-private partnership
model to leverage the adoption of
technology-driven solutions to improve
outcomes for at-risk populations such as
aging Americans living in rural areas.
2. What organizations, groups, and/or,
associations should HHS engage as part
of such a collaborative effort?
HHS encourages all potentially
interested parties—individuals,
associations, governmental, nongovernmental organizations, academic
institutions, and private sector
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
entities—to respond. To facilitate
review of the responses, please
reference the question category and
number in your response.
Dated: November 10, 2020.
Brett P. Giroir,
ADM, U.S. Public Health Service.
[FR Doc. 2020–25328 Filed 11–16–20; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Tick-Borne Disease
Working Group
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As required by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that the Tick-Borne Disease Working
Group (TBDWG) will hold a virtual
meeting. The meeting will be open to
the public. During this meeting, the
TBDWG will finalize and vote on the
2020 report to the HHS Secretary and
Congress. The agenda will be available
on the website prior to the meeting. The
2020 report will address ongoing tickborne disease research, including
research related to causes, prevention,
treatment, surveillance, diagnosis,
diagnostics, and interventions for
individuals with tick-borne diseases;
advances made pursuant to such
research; Federal activities related to
tick-borne diseases; and gaps in tickborne disease research
DATES: The meeting will be held online
via webcast on December 2, 2020, from
approximately 9:00 a.m. to 5:00 p.m. ET
(times are tentative and subject to
change). The confirmed times and
agenda items for the meeting will be
posted on the TBDWG web page at
https://www.hhs.gov/ash/advisorycommittees/tickbornedisease/meetings/
2020-12-2/ when this
information becomes available.
FOR FURTHER INFORMATION CONTACT:
James Berger, Designated Federal Officer
for the TBDWG; Office of Infectious
Disease and HIV/AIDS Policy, Office of
the Assistant Secretary for Health,
Department of Health and Human
Services, Mary E. Switzer Building, 330
C Street SW, Suite L600, Washington,
DC 20024. Email: tickbornedisease@
hhs.gov; Phone: 202–795–7608.
SUPPLEMENTARY INFORMATION: Please
register for the meeting at https://eventsSUMMARY:
E:\FR\FM\17NON1.SGM
17NON1
Agencies
[Federal Register Volume 85, Number 222 (Tuesday, November 17, 2020)]
[Notices]
[Pages 73280-73282]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-25328]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Request for Information--Landscape Analysis To Leverage Novel
Technologies for Chronic Disease Management for Aging Underserved
Populations
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Request for information.
-----------------------------------------------------------------------
SUMMARY: The Office of the Assistant Secretary for Health (OASH) in the
Department of Health and Human Services, in partnership with other
federal agencies, seeks to gain a more comprehensive understanding from
health systems, community based organizations, academic institutions,
non-federal government agencies, innovators, entrepreneurs, non-profit
organizations, and other relevant stakeholders regarding innovative
solutions to chronic disease management leveraging novel technologies
(e.g., artificial intelligence (AI), biosensors, apps, remote
monitoring, 5G) to optimize compliance with evidence-based standards of
care in disease states that cause significant morbidity and mortality
in aging populations in underserved areas (e.g., low income, Medicaid-
eligible, rural). OASH will review information collected in this
request for information (RFI) to better inform federal government
priorities and programs. We also seek to identify opportunities to
strengthen the U.S. healthcare system, as a whole, through public-
private partnerships in data sharing, comprehensive analytics including
AI, and other potential mechanisms. OASH welcomes public feedback
related to how these questions should be addressed and/or potential
solutions. The set of questions is available in the SUPPLEMENTARY
INFORMATION section below.
DATES: To be assured consideration, comments must be received at the
email address provided below, no later than midnight Eastern Time (ET)
on December 22, 2020.
ADDRESSES: Individuals are encouraged to submit responses
electronically to [email protected]. Please indicate ``RFI
RESPONSE'' in the subject line of your email. Submissions received
after the deadline will not be reviewed. Responses to this notice are
not offers and cannot be accepted by the federal government to form a
binding contract or issue a grant. Respond concisely and in plain
language. You may use any structure or layout that
[[Page 73281]]
presents your information well. You may respond to some or all of our
questions, and you can suggest other factors or relevant questions. You
may also include links to online material or interactive presentations.
Clearly mark any proprietary information, and place it in its own
section or file. Your response will become government property, and we
may publish some of its non-proprietary content.
FOR FURTHER INFORMATION CONTACT: Dr. Leith States, Chief Medical
Officer, Office of the Assistant Secretary for Health, (202) 260-2873.
SUPPLEMENTARY INFORMATION:
Background
The Office of the Assistant Secretary for Health--in partnership
with Division of Cardiovascular Sciences, National Heart, Lung, and
Blood Institute, National Institutes of Health; Administration for
Community Living; Agency for Healthcare Quality and Research; United
States Department of Agriculture; Federal Communications Commission;
and the White House Office of Science and Technology Policy --is
interested in resources that enhance quality of life for aging
populations by enabling access to emerging technologies and access to
healthcare services. The COVID-19 response has disrupted access to
routine and emergency healthcare services in many, if not most,
communities. It is estimated that 41 percent of U.S. adults delayed or
avoided medical care due to concerns over COVID-19 transmission.\1\ At
the same time, the pandemic resulted in a strain on the country's
public health and healthcare infrastructure. The populations affected
most by this pandemic are those that experienced inequities in
healthcare at baseline. These inequities are widely understood to be
driven in part by upstream predictors identified as the social
determinants of health (SDOH)--conditions in the environment in which
people are born, live, learn, work, play, worship, and age that affect
a wide range of health, functioning, and quality-of-life outcomes and
risks.\2\
---------------------------------------------------------------------------
\1\ Available at: https://www.cdc.gov/mmwr/volumes/69/wr/mm6936a4.htm#T1_down.
\2\ Available at: https://www.healthypeople.gov/2020/topics-objectives/topic/social-determinants-of-health.
---------------------------------------------------------------------------
Related to these social risk factors, the biological risk factors
most closely associated with increased risk for COVID-19 include age
(65 years and older) and chronic diseases (e.g., cancer, chronic kidney
disease, Alzheimer's disease and related dementias, chronic obstructive
pulmonary disease, heart disease and stroke, diabetes, and obesity).
Underscoring the vulnerability of older adults, the highest rates of
hospitalization and death from COVID-19 are in the older adult
population. In fact, eight in ten COVID-19-related deaths reported in
the United States have been among adults 65 and older.\3\ This
situation is exacerbated in rural communities, for example which,
compared to urban areas, are characterized by a higher percentage of
older adults, higher rates of all-cause mortality, and lower density of
healthcare infrastructure.4 5 The pandemic's further
exacerbation of inequities in healthcare delivery introduces the
opportunity to identify, develop, deploy and evaluate innovative
technological approaches to chronic disease management, as well as the
opportunity to mitigate any introduction of biases that could increase
disparities in healthcare when applying such innovative approaches.
Technological advances (e.g., artificial intelligence (AI) driven
solutions) have great potential to improve health outcomes in the aging
population, particularly for those in underserved areas (e.g., low
income, Medicaid-eligible, rural) by empowering patients and
facilitating integrated healthcare delivery.
---------------------------------------------------------------------------
\3\ Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html.
\4\ Available at: https://www.shepscenter.unc.edu/wp-content/uploads/dlm_uploads/2017/05/Snapshot2017.pdf.
\5\ Available at: https://www.shepscenter.unc.edu/wp-content/uploads/dlm_uploads/2017/08/Regional-Differences-in-Urban-and-Rural-Mortality-Trends.pdf.
---------------------------------------------------------------------------
Leveraging data and applying technologies to improve health for
aging populations in underserved areas is of interest. These include,
for example, advancing data availability from health systems (e.g.,
claims data, electronic health records, surveillance data, etc.),
applying AI to inform behavior change through remote patient
monitoring, and assessing risk to then apply appropriate preventive/
acute care--all to mitigate excess morbidity and mortality from chronic
diseases. The federal government has taken some action to demonstrate
this interest. For example, the Collaborative Aging (in Place) Research
Using Technology (CART) project, a joint effort between the Veterans
Health Administration and the National Institutes of Health, was
launched to support future applications of AI and machine learning to
improve health and healthcare delivery through systematic evaluation of
technologies that enable older adults to remain independent. These
efforts align with the National Artificial Intelligence Research and
Development Strategic Plan, an interagency product released in 2019,
which lays out eight strategic priority areas for federal investment in
AI research and development. The utility of these technologies requires
access to patient monitoring technologies and the data infrastructure
to support analytics and transmission to integrated care teams (e.g.,
primary care, subspecialty care, nursing, pharmacy, social work,
assisted living providers) that can effectively leverage signals that
emerge within this system. To better inform the direction of federal
efforts, OASH and its partners seek information about complementary
technological activities by identifying common themes (e.g., barriers,
opportunities, gaps), highlighting innovative solutions to chronic
disease management, and enhancing the potential for joint public-
private activities to serve aging populations in underserved areas
focusing on the imperative to understand and capitalize on
opportunities to develop, operationalize, and scale innovations in
healthcare and delivery at the individual and population levels for
aging Americans.
Scope and Assumptions
The purpose of this RFI is to gain a more comprehensive
understanding of how health systems, community based organizations,
academic institutions, non-federal government agencies, innovators,
entrepreneurs, non-profit organizations, industry and other relevant
stakeholders are approaching innovative efforts around chronic disease
management (e.g., heart failure, hypertension, chronic lower
respiratory disorders, cognitive impairment) for aging populations in
underserved areas (e.g., rural) by leveraging technology-driven
solutions (e.g., AI), including those designed to optimally utilize
future 5G infrastructure.
Responses may span the continuum of care including but not
limited to detection, prevention (e.g., falls risk reduction),
education, lifestyle modification and behavior change (e.g., diet,
exercise), treatment and rehabilitation of disease.
We are interested in novel approaches and associated
frameworks for collecting data confirming efficacy and/or effectiveness
of technology solutions with demonstrated improvements in one or more
of the following measures: Patient outcomes, access, safety, quality,
cost, and value.
If responses refer to proposed or ongoing projects, the
following information should be included:
[[Page 73282]]
Description, rationale, study design, data sources (to include
harmonization/cleaning of data), funding organization(s), outcomes of
interest, and how such an approach would avoid increasing disparities
in care.
Responses may include implications for scaling an
intervention to broader population levels and other settings.
The definition of ``AI-driven solution'', for the purposes
of this RFI, should be interpreted broadly. We seek an understanding of
innovative activities across the spectrum of care in underserved
settings for older adults.
This RFI also seeks to identify opportunities to
strengthen the U.S. healthcare system through public-private
partnerships. The RFI seeks to identify organizations that would be
interested in discussing the form and function of such collaborations.
Topics
A. Barriers and Opportunities for Technology-Driven Solutions
1. What barriers (e.g., privacy concerns, other clinician and
patient barriers) and opportunities are most relevant for bringing
technology-driven solutions to aging populations in underserved areas?
2. What federal policies currently limit the capacity to deploy and
scale technology-driven solutions for aging populations?
3. What new federal policies could facilitate the success of
technology-driven solutions for aging populations?
4. What are the ways in which technology-driven solutions are
manifested (e.g., software platforms, wearables, robotics, etc.) and
how is the integrity of data collected ensured (e.g., fidelity, and
accuracy of data)?
5. How will training data sets be established and implemented to
drive effective technology solutions that improve chronic disease
outcomes for aging populations in rural areas?
6. How will AI solutions be validated? What metrics will be used to
evaluate the effectiveness of AI/machine learning algorithms?
7. How will healthcare team and patient trust in technology
solutions be addressed? How will legal and ethical issues be addressed
for technology solutions designed for improving chronic disease
outcomes?
8. How will bias and variance be addressed in machine learning
algorithms for this application? How will supervised versus
unsupervised learning be used to develop inferences and patterns from
data sources? What will be the challenges and proposed solutions for
data cleansing and transformation?
9. Will AI deep learning and neural networks approaches and
solutions be appropriate and used for chronic disease improvement for
aging populations?
10. What are the per-person-costs of technology-driven solutions in
the context of this RFI?
B. Key Indicators & Data Sources of Technology-Driven Chronic Disease
Management
1. What key indicators or data sets will be used to perform measure
outcomes (e.g., racial, ethnic, gender, and socioeconomic disparities)?
2. What existing methods, data sources, and analytic approaches are
being used to assess and monitor technology-driven solutions (e.g., AI)
in healthcare systems?
3. What selected health conditions should be addressed as priority
conditions to assess technology-driven capacity to influence access,
timeliness, and quality of healthcare treatment and preventive services
to aging populations living in rural areas?
C. Examples of Health Promotion Using Technology-Driven Solutions
1. Describe novel technology-driven approaches (e.g., AI) that may
prevent the onset, progression, or escalation of chronic disease states
in patients who have decreased frequency of health system interaction
during the COVID-19 pandemic, such as aging Americans living in rural
areas.
2. Outline programs leveraging novel technology-driven approaches
that may prevent increases in morbidity and mortality due to deferred
care for acute medical conditions (e.g., exacerbation of heart failure,
decompensated lower respiratory tract disease).
3. What is the established evidence or evaluation supporting
proposed benefits, and the evaluation of potential harms of AI-driven
solutions such as increased racial bias?
D. Public-Private Partnerships
1. Provide ideas of the form and function of a public-private
partnership model to leverage the adoption of technology-driven
solutions to improve outcomes for at-risk populations such as aging
Americans living in rural areas.
2. What organizations, groups, and/or, associations should HHS
engage as part of such a collaborative effort?
HHS encourages all potentially interested parties--individuals,
associations, governmental, non-governmental organizations, academic
institutions, and private sector entities--to respond. To facilitate
review of the responses, please reference the question category and
number in your response.
Dated: November 10, 2020.
Brett P. Giroir,
ADM, U.S. Public Health Service.
[FR Doc. 2020-25328 Filed 11-16-20; 8:45 am]
BILLING CODE 4150-28-P